Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Papillon study
2024-520419-42-00Phase 4Authorised
- Sponsor
- Saint-Pierre University Hospital
- Start
- Jan 2025
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, Cervical Cancer (CC), Vulval carcinoma and 2 more, sponsored by Saint-Pierre University Hospital. Planned start Jan 2025; status: authorised.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)Vulval carcinomavaginal canceranogenital warts
Beyond the preview
Go deeper on 2024-520419-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520419-42-00.